- Home
- Automated
- List of product information
- POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% INJECTION USP [SIN13888P]
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% INJECTION USP [SIN13888P]
Active ingredients: POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% INJECTION USP
Last updated 26 October 2025
Product Info
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% INJECTION USP
[SIN13888P]
Product information
Active Ingredient and Strength | HYDROUS DEXTROSE - 50 G/1,000 ML |
Dosage Form | INFUSION, SOLUTION |
Manufacturer and Country | B. BRAUN MEDICAL INC. (PARAMETRIC RELEASE) - UNITED STATES |
Registration Number | SIN13888P |
Licence Holder | B. BRAUN SINGAPORE PTE LTD |
Forensic Classification | GENERAL SALE LIST |
Anatomical Therapeutic Chemical (ATC) code | B05BB01 |
INDICATIONS AND USAGE
These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes, calories and water for hydration.
DOSAGE AND ADMINISTRATION
These solutions are for intravenous use only.
Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.
When a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within the lumen of a large vein to minimize venous irritation. Carefully avoid infiltration.
Usually, up to 40 mEq of potassium per liter daily is sufficient to replace normal loss in adults. Typical infusion rates should not exceed 10 mEq per hour or 120 mEq per day. Pediatric patients may require 2 to 3 mEq per kg of body weight daily. See WARNINGS and PRECAUTIONS for pediatric use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Fluid administration should be based on calculated maintenance or replacement fluid requirements for each patient.
Dextrose may be administered to normal individuals at a rate of 0.5 g/kg/hour without producing glycosuria. At the maximum infusion rate of 0.8 g/kg/hour, approximately 95% of the dextrose is retained.
Potassium Chloride in Dextrose and Sodium Chloride Injections USP should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis.
Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
CONTRAINDICATIONS
These solutions are contraindicated where the administration of sodium, potassium or chloride could be clinically detrimental.
Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.